SeekingAlpha · Sep 1, 2026
Shattuck Labs: A Receptor-Side Bet On The TL1A Boom
Shattuck Labs pivots to immunology, focusing on DR3-targeted therapies for IBD, notably SL-325, after discontinuing oncology. Read why STTK stock is a buy.
ST
NASDAQ · STTK
Shattuck Labs, Inc.
Healthcare · Biotechnology
$6.79
Down-$0.18 (-2.65%)
Updated Sep 8, 2026, 6:50 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 154.73M
- P/E ratio
- -4.25
- Dividend yield
- 0.00%
- 52-week range
- $1.45 – $8.33
- Volume
- 677.76K
- Avg. volume
- 297.21K
Price performance
STTK price history
1M range · 20 trading sessions · Daily adjusted prices
STTK closed at $6.79 after 20 trading sessions, down 4.90% for the selected period.
- Last close
- $6.79
- Period change
- -4.90%
- Period low
- $6.79
- Period high
- $8.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $6.84 | $6.88 | $6.6742 | $6.79 | 677.76K |
| Sep 3, 2026 | $6.96 | $7.045 | $6.83 | $6.96 | 563.93K |
| Sep 2, 2026 | $6.91 | $7.28 | $6.77 | $6.91 | 583.53K |
| Sep 1, 2026 | $6.90 | $7.06 | $6.76 | $6.87 | 639.62K |
| Aug 31, 2026 | $6.98 | $7.04 | $6.83 | $7.01 | 751.23K |
| Aug 28, 2026 | $7.55 | $7.59 | $7.035 | $7.04 | 623.14K |
| Aug 27, 2026 | $7.86 | $7.93 | $7.63 | $7.65 | 543.53K |
| Aug 26, 2026 | $8.03 | $8.04 | $7.7901 | $7.90 | 581.84K |
| Aug 25, 2026 | $8.01 | $8.15 | $7.93 | $8.06 | 869.8K |
| Aug 24, 2026 | $7.66 | $8.02 | $7.50 | $7.90 | 2.06M |
| Aug 21, 2026 | $7.35 | $7.55 | $7.25 | $7.53 | 475.59K |
| Aug 20, 2026 | $7.56 | $7.56 | $7.24 | $7.25 | 419.7K |
| Aug 19, 2026 | $7.69 | $7.88 | $7.47 | $7.66 | 767.47K |
| Aug 18, 2026 | $7.32 | $7.47 | $7.04 | $7.45 | 517.15K |
| Aug 17, 2026 | $7.40 | $7.46 | $7.225 | $7.39 | 569.44K |
| Aug 14, 2026 | $7.25 | $7.52 | $6.93 | $7.42 | 640.79K |
| Aug 13, 2026 | $7.65 | $7.65 | $7.26 | $7.32 | 678.02K |
| Aug 12, 2026 | $7.12 | $7.87 | $7.11 | $7.49 | 1.29M |
| Aug 11, 2026 | $7.18 | $7.44 | $7.02 | $7.18 | 1.91M |
| Aug 10, 2026 | $7.25 | $7.6043 | $7.12 | $7.14 | 901.86K |
Latest STTK news
The latest Smart Investors Daily articles mentioning STTK.
Stock researchCompany · Overview
STTK research
Overview
Company profile and research snapshot.
Company profile
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $4.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Raymond James | Strong Buy | — |
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 24, 2026 | JP Morgan | Overweight | — |
| Jul 20, 2026 | Leerink Partners | Outperform | — |
| Jun 9, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 24, 2026
Raymond James Initiates Coverage On Shattuck Labs with Strong Buy Rating, Announces Price Target of $18
Raymond James analyst Martin Auster initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Strong Buy rating and announces Price Target of $18.
Yahoo · Aug 20, 2026
Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?
Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Yahoo · Aug 13, 2026
Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade
The consensus price target hints at an 85.3% upside potential for Shattuck Labs (STTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
